EMA, MIT Form Research Project for Regulatory Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA, MIT Form Research Project for Regulatory Science


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) and the Massachusetts Institute of Technology’s (MIT's) Center for Biomedical Innovation (CBI) and Center for International Studies (CIS) are launching a collaborative research project with a focus on enhancing regulatory science in pharmaceuticals, according to an EMA press release.  

The project, which is scheduled to be completed by December 2011, will be conducted within the framework of CBI’s New Drug Development Paradigms (NEWDIGS) research program in cooperation with EMA and CIS. The project will address the following specific questions:

• How to adapt current regulatory requirements to support the efficient development of safe and effective drugs

• How to incorporate patient valuation of health outcomes and benefit–risk preferences into regulatory decision-making

• How to implement “staggered and progressive” approaches to drug approval

• How to improve the fulfillment of postmarketing regulatory requirements. 

The data and recommendations from this project are expected to link to the implementation of EMA’s Roadmap to 2015, a plan for the agency's strategic development for the next five years, and to the NEWDIGS research program. The project will explore the feasibility of, priorities for, and practical considerations of implementing demonstration projects on some of the issues addressed during the course of the research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here